Navigation Links
Pieris Progresses Proprietary Asthma Program: Validation of,Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma. In studies of its proprietary PRS-060 Anticalin(R) candidate, the Company reports that the protein can be effectively delivered to its target of action via the lungs.

PRS-060 has been selected by Pieris as being specific for a target implicated in a mechanism underlying asthma and other atopic diseases. The mode of action of the Anticalin(R) candidate is via modulation of the site of binding for multiple ligands.

"This important milestone demonstrates the exciting potential of Anticalin(R)-based products for the treatment of respiratory disease," said Dr Andreas Hohlbaum, Director of Science and Preclinical Development of Pieris. "In a simple preclinical biodistribution study quantitating PRS-060 Anticalin(R) delivered via a microspray device, we have already observed about 10-fold higher PRS-060 uptake than that typically obtained with monoclonal antibodies. Our findings have demonstrated the potential to deliver Anticalins(R) through alternative routes to injection and thereby exploit their intrinsic robustness and stability."

"This study confirms the ability of PRS-060 to be formulated in a way ideally suited to its application in asthma, namely in an inhaled preparation for home use," noted Evert Kueppers, Pieris Chief Executive Officer. "These findings continue to support the view that our Anticalin(R) platform, including its recent validation for dual targeting purposes, has enormous potential for application to human diseases that are currently inadequately treated."

The data will be presented for the first time on August 9th 2007 at IBC's Drug Discovery Technology Conference in Bost on, MA, USA.

Pieris is now actively seeking development partners for this program with specialization in product development for respiratory diseases, including asthma.

    Further information is available at http://www.pieris-ag.com

    Anticalin(R) and Duocalin(R) are registered trademarks of Pieris AG.


    For further information, please contact:


    Pieris AG

    Dr Birgit Zech, Senior Manager Business Development

    Phone +49-(0)-8161-1411-400



CONTACT: For further information, please contact: Pieris AG, Dr BirgitZech, Senior Manager Business Development, Phone +49-(0)-8161-1411-400

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
2. Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin in Preclinical Studies
3. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
4. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
5. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
6. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
7. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
8. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
9. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
10. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. Josh ... Mesa, and Chandler, Arizona. , Dr. Olson says the decision to support ...
(Date:6/24/2016)... ... ... Today, InhaleLabs.com (Inhale) offilially launched its site, which aims to ... high quality water pipes within an ideal price range. The site is completely free ... two brothers, Nick and Mike Hunter, who use medical cannabis to heal ailments of ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... An ... that may expose a possible link between head and neck cancer in individuals with ... in the study were evaluated based on whether they had gum disease, brushed their ...
(Date:6/23/2016)... McKinney, Texas (PRWEB) , ... June 23, 2016 , ... ... the special operations community. He turned towards the water to find peace and set ... funds for a veterans charity and turned to the internet. He came across the ...
Breaking Medicine News(10 mins):